204 related articles for article (PubMed ID: 24824663)
1. Hypomania soon after shifting from paroxetine to agomelatine in a middle-aged woman with depression.
Tu KY; Lin PY
Clin Neuropharmacol; 2014; 37(3):82-3. PubMed ID: 24824663
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of agomelatine in previously-treated depressed patients.
Kasper S; Hajak G
Eur Neuropsychopharmacol; 2013 Aug; 23(8):814-21. PubMed ID: 23820051
[TBL] [Abstract][Full Text] [Related]
3. Agomelatine in depression.
Smeraldi E; Delmonte D
Expert Opin Drug Saf; 2013 Nov; 12(6):873-80. PubMed ID: 24033095
[TBL] [Abstract][Full Text] [Related]
4. The mechanism, efficacy, and tolerability profile of agomelatine.
MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
[TBL] [Abstract][Full Text] [Related]
5. Agomelatine: a preliminary review of a new antidepressant.
Zupancic M; Guilleminault C
CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
[TBL] [Abstract][Full Text] [Related]
6. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.
Kennedy SH; Avedisova A; Giménez-Montesinos N; Belaïdi C; de Bodinat C;
Eur Neuropsychopharmacol; 2014 Apr; 24(4):553-63. PubMed ID: 24530273
[TBL] [Abstract][Full Text] [Related]
7. Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA).
Yeh TC; Kao LC; Tzeng NS; Kuo TB; Huang SY; Chang CC; Chang HA
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():60-7. PubMed ID: 26216863
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.
Olié JP; Kasper S
Int J Neuropsychopharmacol; 2007 Oct; 10(5):661-73. PubMed ID: 17477888
[TBL] [Abstract][Full Text] [Related]
9. Treating each and every depressed patient.
Kennedy SH
J Psychopharmacol; 2008 Sep; 22(7 Suppl):19-23. PubMed ID: 18753279
[TBL] [Abstract][Full Text] [Related]
10. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
Bourin M; Prica C
Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
[TBL] [Abstract][Full Text] [Related]
11. Agomelatine: new drug. Adverse effects and no proven efficacy.
Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
[TBL] [Abstract][Full Text] [Related]
12. Agomelatine treatment of major depressive disorder.
Dolder CR; Nelson M; Snider M
Ann Pharmacother; 2008 Dec; 42(12):1822-31. PubMed ID: 19033480
[TBL] [Abstract][Full Text] [Related]
13. The use of antidepressants in clinical practice: focus on agomelatine.
McAllister-Williams RH; Baldwin DS; Haddad PM; Bazire S
Hum Psychopharmacol; 2010 Mar; 25(2):95-102. PubMed ID: 20196187
[TBL] [Abstract][Full Text] [Related]
14. [A comparative evaluation of the efficacy of valdoxan (agomelatine) in recurrent depression and bipolar affective disorder].
Tiuvina NA; Smirnova VN
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(11 Pt 2):53-60. PubMed ID: 23257757
[TBL] [Abstract][Full Text] [Related]
15. Agomelatine, an innovative pharmacological response to unmet needs.
Le Strat Y; Gorwood P
J Psychopharmacol; 2008 Sep; 22(7 Suppl):4-8. PubMed ID: 18753276
[TBL] [Abstract][Full Text] [Related]
16. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
Kasper S; Hamon M
World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
[TBL] [Abstract][Full Text] [Related]
17. Agomelatine, a melatonin agonist with antidepressant properties.
Dubovsky SL; Warren C
Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
[TBL] [Abstract][Full Text] [Related]
18. Major depression is sometimes described as the common cold of psychiatry.
Goodwin GM
J Psychopharmacol; 2008 Sep; 22(7 Suppl):3. PubMed ID: 18753275
[No Abstract] [Full Text] [Related]
19. Major depressive disorder, anhedonia and agomelatine: an open-label study.
Di Giannantonio M; Di Iorio G; Guglielmo R; De Berardis D; Conti CM; Acciavatti T; Cornelio M; Martinotti G
J Biol Regul Homeost Agents; 2011; 25(1):109-14. PubMed ID: 21382280
[TBL] [Abstract][Full Text] [Related]
20. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives.
Pandi-Perumal SR; Trakht I; Srinivasan V; Spence DW; Poeggeler B; Hardeland R; Cardinali DP
World J Biol Psychiatry; 2009; 10(4 Pt 2):342-54. PubMed ID: 18609422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
